A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

Purpose

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Condition

  • Prostatic Neoplasms, Castration-Resistant

Eligibility

Eligible Ages
Between 18 Years and 115 Years
Eligible Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of mCRPC between 01 January 2021 and 31 December 2025. - Male sex at index, where index is the date of initial mCRPC diagnosis. - Age 18 years at index.

Exclusion Criteria

• None

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
mCRPC Cohort Adult male patients with a recent diagnosis of mCRPC in PRECISION.

Recruiting Locations

Novartis
East Hanover, New Jersey 07936

More Details

Status
Recruiting
Sponsor
Novartis Pharmaceuticals

Study Contact

Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com